Feil Family Brain & Mind Research Institute

You are here

Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.

TitleImmediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
Publication TypeJournal Article
Year of Publication2018
AuthorsRanganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS
JournalMult Scler
Volume24
Issue4
Pagination540-542
Date Published2018 04
ISSN1477-0970
Abstract

BACKGROUND: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). Although Immune thrombocytopenia (ITP) has been reported as a secondary autoimmune phenomenon following alemtuzumab infusion, immediate thrombocytopenia during the infusion has not been reported.

OBJECTIVE: We report transient, reversible, self-limiting acute-onset thrombocytopenia during the first course with alemtuzumab.

RESULTS AND CONCLUSION: In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab. Upon chart review, all 22 patients who received alemtuzumab developed an immediate mostly asymptomatic drop in platelet count which returned to normal within 2 months post-infusion.

DOI10.1177/1352458517699876
Alternate JournalMult. Scler.
PubMed ID28287030